Selonsertib (or GS-4997) is a highly selective and potent (ASK1) inhibitor [110] that inhibits ASK1 by competitive binding to the catalytic domain of ASK1 [111]. In vivo in murine model, treatment with GS-4997 reduced fibrosis and steatosis, thus ameliorating the liver disease [112], thereby suggesting ASK1 inhibition as the promising therapeutic approach. The gene discussed is MAP3K5; the disease is liver disorder.